1 Min Read What Is Personalized Immunotherapy?
7 月 14, 2026什么是个性化免疫疗法？
7 月 14, 2026Same cancer, same drug — why did some people survive while others didn't?
编辑部精选 · 照护框架与示意图
Route 1: Neoantigen tumor vaccines
Individual differences in tumor gene mutation profiles · mRNA individualized cancer vaccines (Moderna/BioNTech)
Route 2: TCR-T cell therapy
Individual matching between TCR library and tumor antigen recognition · Extracting high-activity TILs from patient tumors for reinfusion
Route 3: Immune checkpoint individualized stratification
Biomarker-guided treatment selection · TMB, PD-L1, MSI, tumor microenvironment typing
Route 4: Microbiome-immune axis individualized regulation
Gut microbiome's modulation of immunotherapy response · Fecal microbiota transplantation enhancing PD-1 inhibitor response
Personalized Immunotherapy: Four Routes and Clinical Maturity
CORE LOGIC SHIFT:
Old: 'Does this plan work for this type of cancer?' → same treatment, hope for the best
New: 'Does this plan work for THIS patient, at THIS time, at THIS dose and combination?'
= Measure immune fingerprint FIRST, then design/select based on those features
ROUTE 1 — NEOANTIGEN mRNA CANCER VACCINES:
Tumor ≠ same between patients → mutations almost never identical → vaccine must be 1-to-1
Process: whole exome sequencing → AI neoantigen selection (MHC affinity + T cell activation prediction)
→ mRNA synthesis (20–34 neoantigens per patient) → vaccination
Moderna mRNA-4157/V940 + pembrolizumab (KEYNOTE-942 Phase II):
High-risk melanoma recurrence/death risk ↓44% vs. pembrolizumab alone
Manufacturing time: 6–8 weeks (being compressed)
BioNTech BNT122: similar pipeline, multiple tumor types in trials
ROUTE 2 — TIL THERAPY + TCR-T:
TIL = T cells already inside the tumor = 'cells that already know this tumor best'
Extract from resected tumor → in vitro expansion (100s–1000s×) → reinfuse
Rosenberg/NCI 2023 Nature: metastatic cervical cancer TIL → 44% ORR, 3 complete remissions
Lifileucel: FDA approved 2024 (metastatic melanoma) — first commercial TIL product
TCR-T: clone highest-activity tumor-specific TCR → engineer into ordinary T cells → 'precision antenna army'
ROUTE 3 — BIOMARKER STRATIFICATION (already in clinical routine):
PD-L1 (TPS ≥50%): best predictor for PD-1 inhibitor — necessary but not sufficient
TMB-high (≥10 mut/Mb): FDA 2020 pan-cancer approval for pembrolizumab
MSI-H / dMMR: FDA 2017 — FIRST biomarker-based (not organ-based) tumor approval
TME typing: hot (T cell-rich, checkpoint works) → cold (T cell-absent, needs warming first)
'Cold tumor' warming: oncolytic virus + radiation + STING agonists → THEN checkpoint inhibitors
ROUTE 4 — GUT MICROBIOME (most unexpected variable):
Science 2018: THREE independent papers, THREE cancer types → same finding
- prausnitzii + Akkermansia abundance → higher PD-1 inhibitor response
Low diversity = non-responder profile
Penn/Vonderheide 2022 Nature: FMT from complete responders → 30% non-responders convert
'Changing the microbiome can change immunotherapy response' — first direct proof
Mechanism: SCFA → T cell infiltration ↑ · Akkermansia → systemic CD8+ T cell activation
FOR ASIAN/MALAYSIAN READERS:
HLA genotype distribution SIGNIFICANTLY different between Asian and European populations
Neoantigen-MHC affinity predictions from Western databases may NOT apply
Asian-specific HLA + immunogenomics data is critically underrepresented → research opportunity
Frequently Asked Questions